Literature DB >> 15183161

Compound lipophilicity for substrate binding to human P450s in drug metabolism.

David F V Lewis1, Miriam N Jacobs, Maurice Dickins.   

Abstract

Compound lipophilicity is of key importance to P450 binding affinity and enzyme selectivity. Here, lipophilicity is discussed with reference to the human drug-metabolizing P450 enzymes of families CYP1, CYP2 and CYP3. From an extensive compilation of log P values for P450 substrates, and by analysis of relationships between partitioning energy and substrate-binding free energy, the relevance of lipophilicity and other factors pertaining to P450 binding affinity is explained, leading to the formulation of lipophilicity relationships within substrates of each human P450 enzyme involved in drug metabolism. Furthermore, log P values for P450 substrates appear to represent markers for enzyme selectivity. Together with the important roles of hydrogen bonding and pi-pi stacking interaction energies, the desolvation of the P450 active site makes a major contribution to the overall substrate-binding energy and, consequently, a good agreement with experimental information is reported based on this analysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183161     DOI: 10.1016/S1359-6446(04)03115-0

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  26 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers.

Authors:  Eikan Mishima; Emiko Sato; Junya Ito; Ken-Ichi Yamada; Chitose Suzuki; Yoshitsugu Oikawa; Tetsuro Matsuhashi; Koichi Kikuchi; Takafumi Toyohara; Takehiro Suzuki; Sadayoshi Ito; Kiyotaka Nakagawa; Takaaki Abe
Journal:  J Am Soc Nephrol       Date:  2019-11-25       Impact factor: 10.121

3.  Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models.

Authors:  M Paul Gleeson; Andrew M Davis; Kamaldeep K Chohan; Stuart W Paine; Scott Boyer; Claire L Gavaghan; Catrin Hasselgren Arnby; Cecilia Kankkonen; Nan Albertson
Journal:  J Comput Aided Mol Des       Date:  2007-11-22       Impact factor: 3.686

Review 4.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

5.  Evaluation of descriptors and classification schemes to predict cytochrome substrates in terms of chemical information.

Authors:  John H Block; Douglas R Henry
Journal:  J Comput Aided Mol Des       Date:  2008-01-23       Impact factor: 3.686

Review 6.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

7.  Rational engineering of the fungal P450 monooxygenase CYP5136A3 to improve its oxidizing activity toward polycyclic aromatic hydrocarbons.

Authors:  Khajamohiddin Syed; Aleksey Porollo; David Miller; Jagjit S Yadav
Journal:  Protein Eng Des Sel       Date:  2013-07-31       Impact factor: 1.650

8.  Structure-metabolism-relationships in the microsomal clearance of piperazin-1-ylpyridazines.

Authors:  Sabin Llona-Minguez; Artin Ghassemian; Pawel Baranczewski; Matthieu Desroses; Tobias Koolmeister; Per Artursson; Martin Scobie; Thomas Helleday
Journal:  Medchemcomm       Date:  2017-07-04       Impact factor: 3.597

9.  How does the reductase help to regulate the catalytic cycle of cytochrome P450 3A4 using the conserved water channel?

Authors:  Dan Fishelovitch; Sason Shaik; Haim J Wolfson; Ruth Nussinov
Journal:  J Phys Chem B       Date:  2010-05-06       Impact factor: 2.991

Review 10.  Hydrocarbon hydroxylation by cytochrome P450 enzymes.

Authors:  Paul R Ortiz de Montellano
Journal:  Chem Rev       Date:  2010-02-10       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.